Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies that target calcium release–activated calcium (CRAC) channels to treat serious inflammatory and immunologic diseases. The company operates within the biotechnology and pharmaceutical research industry, with a primary emphasis on acute and life-threatening conditions where dysregulated calcium signaling plays a central role. CalciMedica does not currently generate commercial product revenue and is focused on research, development, and clinical advancement of its drug candidates.
The company’s lead product candidate is Auxora™, an intravenous small-molecule CRAC channel inhibitor being evaluated for indications including acute pancreatitis, acute respiratory distress syndrome (ARDS), and other inflammatory conditions. CalciMedica’s strategic positioning is based on its specialized expertise in calcium signaling biology and a differentiated mechanism of action that is intended to modulate inflammatory responses without broadly suppressing the immune system. The company was founded in 2006 and has evolved from early-stage discovery research into a publicly traded clinical-stage organization following its initial public offering in 2020.
Business Operations
CalciMedica’s operations are centered on drug discovery and clinical development, with substantially all activities dedicated to advancing Auxora™ through clinical trials and regulatory pathways. The company conducts its research and development through a combination of internal scientific teams and outsourced clinical research organizations, a model typical of early-stage biotechnology companies. Revenue generation is not yet operational, and funding is primarily derived from equity offerings and strategic financing activities.
The company’s core assets include its proprietary CRAC channel inhibition technology and associated intellectual property portfolio. CalciMedica maintains collaborations with academic institutions and clinical investigators to support preclinical research and multicenter clinical trials. As of publicly available disclosures, the company does not report revenue-generating subsidiaries or commercial joint ventures, and its business remains focused on a single operating segment dedicated to therapeutic development.
Strategic Position & Investments
CalciMedica’s strategic direction is centered on advancing Auxora™ through late-stage clinical development for high-unmet-need inflammatory diseases, particularly in hospital and critical care settings. Growth initiatives are focused on expanding clinical indications, generating robust clinical data, and pursuing regulatory approvals in the United States and internationally. The company has also indicated interest in exploring additional indications where CRAC channel inhibition may offer therapeutic benefit.
Investment activity has primarily consisted of internal investment in research and development rather than acquisitions. CalciMedica does not currently report ownership of diversified portfolio companies, and no major mergers or acquisitions have been disclosed in recent public filings. Emerging focus areas include severe inflammatory disorders and immune-mediated conditions, leveraging the same underlying calcium signaling platform.
Geographic Footprint
CalciMedica is headquartered in the United States, with its principal executive offices located in California. The company’s operational footprint is primarily domestic, reflecting its status as a development-stage biotechnology firm without commercial manufacturing or sales infrastructure.
Despite its U.S.-based headquarters, CalciMedica maintains an international presence through global clinical trial sites and research collaborations in North America, Europe, and other regions as required for multinational studies. These activities provide the company with exposure to international regulatory frameworks and patient populations, although it does not currently maintain permanent operational facilities outside the United States.
Leadership & Governance
CalciMedica was founded by Randall J. Kaufman, who played a key role in establishing the company’s scientific and strategic foundation in calcium signaling therapeutics. The current leadership team emphasizes disciplined clinical development, data-driven decision-making, and a focus on addressing severe diseases with limited treatment options.
Key executives publicly associated with CalciMedica include:
- Rachel Leheny – President & Chief Executive Officer
- Randall J. Kaufman – Founder & Board Member
- Stephen R. Hufford – Chief Medical Officer
- Patrick M. O’Neill – Chief Financial Officer
The company is governed by a board of directors with experience in biotechnology, clinical development, and public company oversight. Leadership communications emphasize advancing shareholder value through clinical milestones, regulatory progress, and prudent capital management.